SBIR Phase I: A Platform for Label-Free, Numerous-Marker-Based Isolation of Functionally Preserved Single Cancer Stem Cells

SBIR 第一阶段：用于无标记、基于大量标记物的功能保存的单个癌症干细胞分离的平台

• 批准号: 1913412
• 负责人: Hany Nassef
• 金额: $ 22.5万
• 依托单位: Nodexus Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2020-02-29
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1913412&HistoricalAwards=false
• 关键词: SBIR; Phase; Platform; Label; Free

The broader impact/commercial potential of this SBIR Phase I project leverages node-pore sensing with multi-marker screening for viable, functionally-preserved isolation of single urothelial carcinoma of the bladder stem cells. This tool will help enable more comprehensive biomarker discovery and facilitate the development of targeted therapies. Ultimately, this solution will allow for clinical, academic, and industrial researchers to selectively isolate single cells from fragile primary bladder biopsy subpopulations for downstream analysis and personalized treatment development in the longer term. The ability to screen for numerous parameters and isolate target urothelial carcinoma of the bladder stem cells in a walk-up usable, accessible, and low-cost manner will enable downstream functional studies that will help lead to improved patient outcomes. In conjunction with the business opportunity here, there is projected to be a significant positive impact on research output and publications that will be enabled by the introduction of a low-cost urothelial carcinoma of the bladder stem cell isolation instrument to research, industrial/biopharma, and clinical facilities.This SBIR Phase I project involves a multi-parametric approach leveraging label-free node-pore sensing and low-shear microfluidics for viable single-cell sorting and dispensing while preserving viability and functional characteristics for downstream assays. Characterization and isolation of single, live functionally-preserved urothelial carcinoma of the bladder cancer stem cells is pivotal for the determination of universally accepted, clinically-accurate biomarkers for early cancer detection as well as optimized targeted therapy development. This project is aimed at delivering easy access to these cells without requiring extensive experimental design and tuning, enabling operation by untrained, non-expert users. Using the novel detection and isolation methodologies, the platform can be used to unveil masked heterogeneity and enable downstream functional studies (such as growth, invasion, and chemotherapeutic resistance) on individually isolated, viable, and functionally-preserved isolated urothelial carcinoma of the bladder stem cells.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该SBIR I期项目具有更广泛的影响/商业潜力，利用节点孔传感和多标记筛选，分离出可行的、功能保存的单个膀胱尿路上皮癌干细胞。该工具将有助于实现更全面的生物标志物发现，并促进靶向治疗的发展。最终，该解决方案将允许临床、学术和工业研究人员选择性地从脆弱的原发性膀胱活检亚群中分离单细胞，用于下游分析和长期的个性化治疗开发。筛选众多参数的能力和分离目标膀胱尿路上皮癌干细胞的能力，以一种可用的、可获得的和低成本的方式，将使下游功能研究成为可能，这将有助于改善患者的预后。结合这里的商业机会，预计通过向研究、工业/生物制药和临床设施引入低成本的膀胱尿路上皮癌干细胞分离仪器，将对研究产出和出版物产生重大的积极影响。SBIR一期项目涉及多参数方法，利用无标签节点孔传感和低剪切微流体进行可行的单细胞分选和分配，同时保留下游分析的可行性和功能特征。单个功能保存的尿路上皮癌干细胞的鉴定和分离对于确定普遍接受的、临床准确的早期癌症检测生物标志物以及优化靶向治疗开发至关重要。该项目旨在提供方便的访问这些细胞，而不需要大量的实验设计和调整，使未经训练的非专业用户也能操作。使用新的检测和分离方法，该平台可用于揭示被掩盖的异质性，并对单独分离的、存活的和功能保存的分离的膀胱尿路上皮癌干细胞进行下游功能研究（如生长、侵袭和化疗耐药性）。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。